Aerie Pharmaceuticals Inc., of Irvine, Calif., named Barry Ivin site director of its new manufacturing plant in Athlone, Ireland. The company also appointed Huan Sheng director clinical research and drug safety. Read More

Eli Lilly and Co., of Indianapolis, said the label for Trulicity (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is now updated to include use in combination with basal insulin for adults with type 2 diabetes. Read More

Can-Fite Biopharma Ltd., of Petach Tikva, Israel, said it is set to start patient enrollment in the second quarter for its phase III trial testing lead candidate piclidenoson, an A3 adenosine receptor agonist, as a first-line treatment for rheumatoid arthritis. Read More

Galena Biopharma Inc., of San Ramon, Calif., priced a public offering of units with anticipated gross proceeds of $17 million. Each unit consists of one full share of common stock and a warrant to purchase one share and is priced at $1 per unit. Read More

In an attempt to checkmate President Donald Trump's executive order to reduce the U.S. regulatory burden, a labor union and two nonprofit advocacy groups are turning to the courts to take the president's "two-for-one" regulatory policy out of play. Read More

HYDERABAD, India – Smaller domestic and regional pharmaceutical and biotech companies are expanding their footprint in Asia while using the region as a launch pad to emerge as significant global players and to tap a growing ecosystem of biotech-related business. Many of those companies are in India, where policy initiatives and plenty of unmet needs have come together to encourage investment in the space. Read More

The era when a clinical failure in Alzheimer's disease (AD) meant major headlines, stock sell-offs and conference calls attempting damage control seems to be over, as two pharma giants – this year and last year – practically murmured their mid and late-stage blowups with AD candidates in the 5HT6 receptor antagonist class. Read More

LONDON – One of Europe's leading biotech venture capital investors has warned the U.K. could see its top science assets moved offshore for commercialization once the country leaves the EU. Read More

Six months later than first expected, FDA approval for Amgen Inc.'s secondary hyperparathyroidism (SHPT) treatment, Parsabiv (etelcalcetide), has arrived. Read More